NCT03550794View on ClinicalTrials.gov

Thiamine as a Renal Protective Agent in Septic Shock

PHASE2CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

September 4, 2018

Primary Completion Date

April 5, 2022

Study Completion Date

April 5, 2022

Conditions
SepsisKidney InjuryThiamine Deficiency
Interventions
DRUG

Thiamine Hydrochloride

Thiamine hydrochloride is a water soluble vitamin (vitamin B1). 200mg of thiamine hydrochloride in 50ml 0.9%NACL will be administered twice daily for 3 days.

DRUG

Placebo

50ml of 0.9% NACL will serve as the placebo

Trial Locations (4)

10467

Montefiore Medical Center, New York

11030

Northshore University Hospital, Manhasset

11040

Long Island Jewish Hospital, Queens

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
lead

Beth Israel Deaconess Medical Center

OTHER

NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock | Biotech Hunter | Biotech Hunter